Porfiromycin (CAS 801-52-5)
QUICK LINKS
Porfiromycin is a compound that is of particular interest in the field of biochemistry, where it is studied for its antibiotic properties and its mechanism of action. Research on porfiromycin largely focuses on its interaction with DNA, exploring how it forms adducts that can inhibit DNA replication and transcription. These studies contribute to a broader understanding of the biochemical pathways involved in the regulation of gene expression. Additionally, porfiromycin′s ability to generate reactive oxygen species upon activation is examined for its effects on cellular structures, including nucleic acids and proteins. The structure of porfiromycin, which is closely related to that of mitomycin C, prompts comparative studies to elucidate structural-activity relationships and the molecular basis of its activity. Furthermore, investigations into the bioreductive activation of porfiromycin are significant for revealing how certain cellular enzymes can modulate its action.
Porfiromycin (CAS 801-52-5) References
- Effects of mitomycin C and porfiromycin on exponentially growing and plateau phase cultures. | Rockwell, S. and Hughes, CS. 1994. Cell Prolif. 27: 153-63. PMID: 10465006
- Isolation and identification of metabolites of porfiromycin formed in the presence of a rat liver preparation. | Lang, W., et al. 2000. J Pharm Sci. 89: 191-8. PMID: 10688748
- PHENETHYL ALCOHOL SYNERGISM WITH MITOMYCIN C, PORFIROMYCIN, AND STREPTONIGRIN. | WHITE, JR. and WHITE, HL. 1964. Science. 145: 1312-3. PMID: 14173417
- Effect of deficiencies in DNA repair on the toxicity of mitomycin C and porfiromycin to CHO cells under aerobic and hypoxic conditions. | Hughes, CS., et al. 1991. Cancer Commun. 3: 29-35. PMID: 1899798
- Studies on the mechanism of resistance to mitomycin C and porfiromycin in a human cell strain derived from a cancer-prone individual. | Marshall, RS., et al. 1991. Biochem Pharmacol. 41: 1351-60. PMID: 1902110
- Distribution of porfiromycin in EMT6 solid tumors and normal tissues of BALB/c mice. | Keyes, SR., et al. 1991. J Natl Cancer Inst. 83: 632-7. PMID: 2023281
- Activity of C-7 substituted cyclic acetal derivatives of mitomycin C and porfiromycin against hypoxic and oxygenated EMT6 carcinoma cells in vitro and in vivo. | Rockwell, S., et al. 1991. Cancer Commun. 3: 191-8. PMID: 2049227
- Addition of a hypoxic cell selective cytotoxic agent (mitomycin C or porfiromycin) to Fluosol-DA/carbogen/radiation. | Holden, SA., et al. 1990. Radiother Oncol. 18: 59-70. PMID: 2113698
- Porfiromycin disposition in oxygen-modulated P388 cells. | Pan, SS. 1990. Cancer Chemother Pharmacol. 27: 187-93. PMID: 2265454
- Modulation of the cytotoxicity of porfiromycin by dicoumarol in vitro and in vivo. | Rockwell, S., et al. 1989. Anticancer Res. 9: 817-20. PMID: 2479329
- Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells. | Fracasso, PM. and Sartorelli, AC. 1986. Cancer Res. 46: 3939-44. PMID: 3089583
- Metabolites and DNA adduct formation from flavoenzyme-activated porfiromycin. | Pan, SS. and Iracki, T. 1988. Mol Pharmacol. 34: 223-8. PMID: 3412325
- Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro. | Keyes, SR., et al. 1985. Cancer Res. 45: 3642-5. PMID: 3926306
- pH-dependent inactivation of DT-diaphorase by mitomycin C and porfiromycin. | Siegel, D., et al. 1993. Mol Pharmacol. 44: 1128-34. PMID: 8264549
- Effect of pH on DNA alkylation by enzyme-activated mitomycin C and porfiromycin. | Yu, F. and Pan, SS. 1993. Mol Pharmacol. 43: 863-9. PMID: 8391116
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Porfiromycin, 1 mg | sc-476298 | 1 mg | $439.00 |